A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)
Completed
AbbVie (prior sponsor, Abbott)
Phase 2
2011-09-01
The purpose of this study was to evaluate the efficacy, safety and pharmacokinetics of
ABT-450/r when given together with ABT-267 and with and without RBV in treatment-naïve
participants with genotype 1, 2 or 3 chronic HCV infection.
A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection
Completed
AbbVie (prior sponsor, Abbott)
Phase 2
2012-07-01
This study evaluated the safety, tolerability, antiviral activity, and pharmacokinetics of
ABT-450 (also known as paritaprevir) with ritonavir (ABT-450/r) and ABT-267 (also known as
ombitasvir) in adult Japanese patients with chronic hepatitis C virus genotype 1b (HCV GT1b)
or genotype 2 (HCV GT2) infection who were previous treated with pegylated
interferon/ribavirin (pegIFN/RBV).
A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C
Completed
AbbVie (prior sponsor, Abbott)
Phase 3
2012-08-01
The purpose of this study is to evaluate the safety and antiviral activity of
ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267; ABT-450 also known as paritaprevir; ABT-267
also known as ombitasvir) and ABT-333 (also known as dasabuvir) with and without ribavirin
(RBV) in patients with chronic hepatitis C virus genotype 1b (HCV GT1b) infection without
cirrhosis.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
